NPS-2143: Treatment of osteoporosis calcilytic

Drugs of the Future

Volumn 27, Issue 2, 2002, Pages 140-142

  Doggrell, Sheila A ^a   Del Fresno, M ^a   Castaner J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 6 [3 [1,1 DIMETHYL 2 (2 NAPHTHYL)ETHYLAMINO] 2 HYDROXYPROPOXY]BENZONITRILE; CALCIUM CHANNEL STIMULATING AGENT; ESTROGEN; G PROTEIN COUPLED RECEPTOR; PARATHYROID HORMONE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BONE DENSITY; BONE MINERAL; CELL SURFACE; DRUG POTENTIATION; HORMONE RELEASE; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OVARIECTOMY; PARATHYROID GLAND; PARATHYROID HORMONE BLOOD LEVEL;

EID: 0036254258     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2002.027.02.656406     Document Type: Article

References (7)

1. Novel treatments for osteoporosis
2. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
3. Physiology and pathophysiology of the extracellular calcium-sensing receptor
4. 2+ receptor antagonists that stimulate secretion of parathyroid hormone
5. Plasma levels of parathyroid hormone that induce anabolic effects in bone of ovariectomized rats can be achieved by stimulation of endogenous hormone secretion
6. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats